November is the International Lung Cancer Awareness Month, and lung cancer has become the cancer with the highest incidence in China. According to relevant authoritative data, about 82 new cases of lung cancer occur every year810,000 cases and about 65 deathsThere are 700,000 cases, and the number of new cases and deaths ranks first among malignant tumors in China, and the trend of younger lung cancer is becoming more and more prominent.
Be wary of the "king of cancers".
Lung cancer is a malignant tumor originating from the bronchial mucosa or glands of the lungs, which can be caused by smoking, air pollution, diet, genetics and other factors, and is clinically manifested as cough, blood or hemoptysis in sputum, chest pain, etc.
Jinyu Testing mentioned that due to the characteristics of lung cancer, lung cancer is not easy to find, so many patients are already in the advanced stage when they visit the hospital, and the possibility of recovery is greatly reduced. However, if early detection and accurate detection of diseases can increase the 5-year survival rate of patients by 10 times, bring better prognosis and prolong life expectancy.
In the past, surgery, radiation and drugs were often used for clinical lung cancer, but at this stage, with the continuous progress of medical technology, immunity and targeting are also one of the good and efficient methods. In addition, for the early detection of lung cancer, fluorescent bronchoscopy, CT, magnetic resonance, EBUS-TBNA, PET-CT, and genetic testing have been widely used in clinical diagnosis and treatment.
Launched a whole-process testing guide for lung cancer screening and diagnosis
In order to help stay away from the risk of lung cancer, Jinyu Testing has sorted out a number of examination items and sorted out a whole-process testing guide for lung cancer screening and diagnosis, in order to better understand the diagnosis and treatment process of lung cancer for clinicians and patients.
In the screening process, the most commonly used method is low-dose spiral CT of the chest, but its sensitivity for the detection of lung cancer before or in the early stage of nodule formation is weak, and it is prone to false positives. At present, Jinyu Testing recommends paying attention to lung cancer gene methylation and conducting lung cancer gene methylation detection, which has the characteristics of earlier, more accurate, safer and more convenient.
In the diagnosis process, pathological examination is the hard standard for the diagnosis of lung cancer, which can clarify the nature of the tumor, pathological classification, clinical stage, etc., and play a key role in the follow-up. If lung cancer is in the early stage, Jinyu Testing recommends that surgical resection is the first treatment.
In the drug guidance link, targeted drugs provide effective help for lung cancer precision**. Clinical studies have shown that identifying the genetic variation of tumor cells through genetic testing can play a certain role in guiding the use of targeted drugs. Recently, Jinyu Testing has launched the "Huimin 3000" tumor test**, which covers 17 types of cancer, including lung cancer, and patients only need to pay no more than 3,000 yuan to complete tumor genetic testing, which greatly reduces the economic burden of genetic testing for patients.
In the follow-up process, CTC and MRD, as new indicators, are gradually becoming a research hotspot in the diagnosis and treatment of lung cancer and other malignant tumors.
At present, Jinyu Testing is one of the few medical laboratories in the industry that can provide full-process services for lung cancer, which can effectively meet the different testing needs of clinicians and patients.
Disclaimer: The content of the article published or ** and indicated from other ** on this platform is only for the reference of communication Xi, and does not mean that it agrees with its views or confirms the authenticity of its content, and is not used as any investment basis.